التهاب الفقار اللاصق عند فشل مضادات الالتهاب غير الستيرويدية في السيطرة على آلام الظهر وتيبس العمود الفقري

References

• TNFi, IL-17i or JAKi should be considered in patients with persistently high disease activity despite conventional treatments (figure 1); current practice is to start a TNFi or IL-17i.
• This means non-pharmacological treatment and the use of at least two NSAIDs, in the maximum dose used in axSpA, over a total period of 4 weeks.
• Figure 3 summarises the criteria for continuation, namely that after at least 12 weeks of treatment, the disease activity has substantially decreased, as assessed by the ASDAS clinical important improvement, that is, improvement in ASDAS ≥1.1, together with the positive opinion from the rheumatologist to continue.